Finance Monthly M&A Awards 2019 - Winners Edition

20 Legal Adviser to Bristol Myers Squibb Lead Financial Adviser to Bristol Myers Squibb Legal Adviser to Celgene BRISTOL MYERS SQUIBB ACQUIRES CELGENE FOR $74BN USA MERGERS & ACQUISITIONS Pharmaceutical INTRODUCTION Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. DEAL OF THE YEAR 2019